Summary
According to APO Research, the global HER2 Antibody market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for HER2 Antibody is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for HER2 Antibody is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the HER2 Antibody market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for HER2 Antibody is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the HER2 Antibody market include Novartis AG, Pfizer, InvivoGen, Genentech Inc, Celltrion, Bio-Techne, Biocon Limited and Abnova Corporation, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for HER2 Antibody, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of HER2 Antibody, also provides the value of main regions and countries. Of the upcoming market potential for HER2 Antibody, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the HER2 Antibody revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global HER2 Antibody market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global HER2 Antibody company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
HER2 Antibody Segment by Company
Novartis AG
Pfizer
InvivoGen
Genentech Inc
Celltrion
Bio-Techne
Biocon Limited
Abnova Corporation
HER2 Antibody Segment by Type
Ado-trastuzumab Emtansine
Lapatinib
Pertuzumab
Trastuzumab
Everolimus
HER2 Antibody Segment by Application
Hospital
Medical Center
HER2 Antibody Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global HER2 Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the HER2 Antibody key companies, revenue, market share, and recent developments.
3. To split the HER2 Antibody breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions HER2 Antibody market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify HER2 Antibody significant trends, drivers, influence factors in global and regions.
6. To analyze HER2 Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HER2 Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of HER2 Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HER2 Antibody.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global HER2 Antibody industry.
Chapter 3: Detailed analysis of HER2 Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of HER2 Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of HER2 Antibody in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
- Market Overview
- Product Definition
- Global HER2 Antibody Market Size, 2020 VS 2024 VS 2031
- Global HER2 Antibody Market Size (2020-2031)
- Assumptions and Limitations
- Study Goals and Objectives
- HER2 Antibody Market Dynamics
- HER2 Antibody Industry Trends
- HER2 Antibody Industry Drivers
- HER2 Antibody Industry Opportunities and Challenges
- HER2 Antibody Industry Restraints
- HER2 Antibody Market by Company
- Global HER2 Antibody Company Revenue Ranking in 2024
- Global HER2 Antibody Revenue by Company (2020-2025)
- Global HER2 Antibody Company Ranking (2023-2025)
- Global HER2 Antibody Company Manufacturing Base and Headquarters
- Global HER2 Antibody Company Product Type and Application
- Global HER2 Antibody Company Establishment Date
- Market Competitive Analysis
- Global HER2 Antibody Market Concentration Ratio (CR5 and HHI)
- Global Top 5 and 10 Company Market Share by Revenue in 2024
- 2024 HER2 Antibody Tier 1, Tier 2, and Tier 3 Companies
- Mergers and Acquisitions Expansion
- HER2 Antibody Market by Type
- HER2 Antibody Type Introduction
- Ado-trastuzumab Emtansine
- Lapatinib
- Pertuzumab
- Trastuzumab
- Everolimus
- Global HER2 Antibody Sales Value by Type
- Global HER2 Antibody Sales Value by Type (2020 VS 2024 VS 2031)
- Global HER2 Antibody Sales Value by Type (2020-2031)
- Global HER2 Antibody Sales Value Share by Type (2020-2031)
- HER2 Antibody Type Introduction
- HER2 Antibody Market by Application
- HER2 Antibody Application Introduction
- Hospital
- Medical Center
- Global HER2 Antibody Sales Value by Application
- Global HER2 Antibody Sales Value by Application (2020 VS 2024 VS 2031)
- Global HER2 Antibody Sales Value by Application (2020-2031)
- Global HER2 Antibody Sales Value Share by Application (2020-2031)
- HER2 Antibody Application Introduction
- HER2 Antibody Regional Value Analysis
- Global HER2 Antibody Sales Value by Region: 2020 VS 2024 VS 2031
- Global HER2 Antibody Sales Value by Region (2020-2031)
- Global HER2 Antibody Sales Value by Region: 2020-2025
- Global HER2 Antibody Sales Value by Region (2026-2031)
- North America
- North America HER2 Antibody Sales Value (2020-2031)
- North America HER2 Antibody Sales Value Share by Country, 2024 VS 2031
- Europe
- Europe HER2 Antibody Sales Value (2020-2031)
- Europe HER2 Antibody Sales Value Share by Country, 2024 VS 2031
- Asia-Pacific
- Asia-Pacific HER2 Antibody Sales Value (2020-2031)
- Asia-Pacific HER2 Antibody Sales Value Share by Country, 2024 VS 2031
- South America
- South America HER2 Antibody Sales Value (2020-2031)
- South America HER2 Antibody Sales Value Share by Country, 2024 VS 2031
- Middle East & Africa
- Middle East & Africa HER2 Antibody Sales Value (2020-2031)
- Middle East & Africa HER2 Antibody Sales Value Share by Country, 2024 VS 2031
- HER2 Antibody Country-level Value Analysis
- Global HER2 Antibody Sales Value by Country: 2020 VS 2024 VS 2031
- Global HER2 Antibody Sales Value by Country (2020-2031)
- Global HER2 Antibody Sales Value by Country (2020-2025)
- Global HER2 Antibody Sales Value by Country (2026-2031)
- USA
- USA HER2 Antibody Sales Value Growth Rate (2020-2031)
- USA HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- USA HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- Canada
- Canada HER2 Antibody Sales Value Growth Rate (2020-2031)
- Canada HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- Canada HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- Mexico
- Mexico HER2 Antibody Sales Value Growth Rate (2020-2031)
- Mexico HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- Mexico HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- Germany
- Germany HER2 Antibody Sales Value Growth Rate (2020-2031)
- Germany HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- Germany HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- France
- France HER2 Antibody Sales Value Growth Rate (2020-2031)
- France HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- France HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- U.K.
- U.K. HER2 Antibody Sales Value Growth Rate (2020-2031)
- U.K. HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- U.K. HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- Italy
- Italy HER2 Antibody Sales Value Growth Rate (2020-2031)
- Italy HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- Italy HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- Spain
- Spain HER2 Antibody Sales Value Growth Rate (2020-2031)
- Spain HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- Spain HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- Russia
- Russia HER2 Antibody Sales Value Growth Rate (2020-2031)
- Russia HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- Russia HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- Netherlands
- Netherlands HER2 Antibody Sales Value Growth Rate (2020-2031)
- Netherlands HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- Netherlands HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- Nordic Countries
- Nordic Countries HER2 Antibody Sales Value Growth Rate (2020-2031)
- Nordic Countries HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- Nordic Countries HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- China
- China HER2 Antibody Sales Value Growth Rate (2020-2031)
- China HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- China HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- Japan
- Japan HER2 Antibody Sales Value Growth Rate (2020-2031)
- Japan HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- Japan HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- South Korea
- South Korea HER2 Antibody Sales Value Growth Rate (2020-2031)
- South Korea HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- South Korea HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- India
- India HER2 Antibody Sales Value Growth Rate (2020-2031)
- India HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- India HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- Australia
- Australia HER2 Antibody Sales Value Growth Rate (2020-2031)
- Australia HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- Australia HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- Southeast Asia
- Southeast Asia HER2 Antibody Sales Value Growth Rate (2020-2031)
- Southeast Asia HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- Southeast Asia HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- Brazil
- Brazil HER2 Antibody Sales Value Growth Rate (2020-2031)
- Brazil HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- Brazil HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- Argentina
- Argentina HER2 Antibody Sales Value Growth Rate (2020-2031)
- Argentina HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- Argentina HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- Chile
- Chile HER2 Antibody Sales Value Growth Rate (2020-2031)
- Chile HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- Chile HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- Colombia
- Colombia HER2 Antibody Sales Value Growth Rate (2020-2031)
- Colombia HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- Colombia HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- Peru
- Peru HER2 Antibody Sales Value Growth Rate (2020-2031)
- Peru HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- Peru HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- Saudi Arabia
- Saudi Arabia HER2 Antibody Sales Value Growth Rate (2020-2031)
- Saudi Arabia HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- Saudi Arabia HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- Israel
- Israel HER2 Antibody Sales Value Growth Rate (2020-2031)
- Israel HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- Israel HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- UAE
- UAE HER2 Antibody Sales Value Growth Rate (2020-2031)
- UAE HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- UAE HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- Turkey
- Turkey HER2 Antibody Sales Value Growth Rate (2020-2031)
- Turkey HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- Turkey HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- Iran
- Iran HER2 Antibody Sales Value Growth Rate (2020-2031)
- Iran HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- Iran HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- Egypt
- Egypt HER2 Antibody Sales Value Growth Rate (2020-2031)
- Egypt HER2 Antibody Sales Value Share by Type, 2024 VS 2031
- Egypt HER2 Antibody Sales Value Share by Application, 2024 VS 2031
- Company Profiles
- Novartis AG
- Novartis AG Comapny Information
- Novartis AG Business Overview
- Novartis AG HER2 Antibody Revenue and Gross Margin (2020-2025)
- Novartis AG HER2 Antibody Product Portfolio
- Novartis AG Recent Developments
- Pfizer
- Pfizer Comapny Information
- Pfizer Business Overview
- Pfizer HER2 Antibody Revenue and Gross Margin (2020-2025)
- Pfizer HER2 Antibody Product Portfolio
- Pfizer Recent Developments
- InvivoGen
- InvivoGen Comapny Information
- InvivoGen Business Overview
- InvivoGen HER2 Antibody Revenue and Gross Margin (2020-2025)
- InvivoGen HER2 Antibody Product Portfolio
- InvivoGen Recent Developments
- Genentech Inc
- Genentech Inc Comapny Information
- Genentech Inc Business Overview
- Genentech Inc HER2 Antibody Revenue and Gross Margin (2020-2025)
- Genentech Inc HER2 Antibody Product Portfolio
- Genentech Inc Recent Developments
- Celltrion
- Celltrion Comapny Information
- Celltrion Business Overview
- Celltrion HER2 Antibody Revenue and Gross Margin (2020-2025)
- Celltrion HER2 Antibody Product Portfolio
- Celltrion Recent Developments
- Bio-Techne
- Bio-Techne Comapny Information
- Bio-Techne Business Overview
- Bio-Techne HER2 Antibody Revenue and Gross Margin (2020-2025)
- Bio-Techne HER2 Antibody Product Portfolio
- Bio-Techne Recent Developments
- Biocon Limited
- Biocon Limited Comapny Information
- Biocon Limited Business Overview
- Biocon Limited HER2 Antibody Revenue and Gross Margin (2020-2025)
- Biocon Limited HER2 Antibody Product Portfolio
- Biocon Limited Recent Developments
- Abnova Corporation
- Abnova Corporation Comapny Information
- Abnova Corporation Business Overview
- Abnova Corporation HER2 Antibody Revenue and Gross Margin (2020-2025)
- Abnova Corporation HER2 Antibody Product Portfolio
- Abnova Corporation Recent Developments
- Novartis AG
- Concluding Insights
- Appendix
- Reasons for Doing This Study
- Research Methodology
- Research Process
- Authors List of This Report
- Data Source
- Secondary Sources
- Primary Sources
List of Tables
Table 1 | :HER2 Antibody Industry Trends |
Table 2 | :HER2 Antibody Industry Drivers |
Table 3 | :HER2 Antibody Industry Opportunities and Challenges |
Table 4 | :HER2 Antibody Industry Restraints |
Table 5 | :Global HER2 Antibody Revenue by Company (US$ Million) & (2020-2025) |
Table 6 | :Global HER2 Antibody Revenue Share by Company (2020-2025) |
Table 7 | :Global HER2 Antibody Company Ranking, (2023-2025) & (US$ Million) |
Table 8 | :Global HER2 Antibody Key Company Manufacturing Base & Headquarters |
Table 9 | :Global HER2 Antibody Company, Product Type & Application |
Table 10 | :Global HER2 Antibody Company Establishment Date |
Table 11 | :Global Company Market Concentration Ratio (CR5 and HHI) |
Table 12 | :Global HER2 Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2024) |
Table 13 | :Mergers & Acquisitions, Expansion |
Table 14 | :Significant Companies of Ado-trastuzumab Emtansine |
Table 15 | :Significant Companies of Lapatinib |
Table 16 | :Significant Companies of Pertuzumab |
Table 17 | :Significant Companies of Trastuzumab |
Table 18 | :Significant Companies of Everolimus |
Table 19 | :Global HER2 Antibody Sales Value by Type 2020 VS 2024 VS 2031 (US$ Million) |
Table 20 | :Global HER2 Antibody Sales Value by Type (2020-2025) & (US$ Million) |
Table 21 | :Global HER2 Antibody Sales Value by Type (2026-2031) & (US$ Million) |
Table 22 | :Global HER2 Antibody Sales Value Share by Type (2020-2025) |
Table 23 | :Global HER2 Antibody Sales Value Share by Type (2026-2031) |
Table 24 | :Significant Companies of Hospital |
Table 25 | :Significant Companies of Medical Center |
Table 26 | :Global HER2 Antibody Sales Value by Application 2020 VS 2024 VS 2031 (US$ Million) |
Table 27 | :Global HER2 Antibody Sales Value by Application (2020-2025) & (US$ Million) |
Table 28 | :Global HER2 Antibody Sales Value by Application (2026-2031) & (US$ Million) |
Table 29 | :Global HER2 Antibody Sales Value Share by Application (2020-2025) |
Table 30 | :Global HER2 Antibody Sales Value Share by Application (2026-2031) |
Table 31 | :Global HER2 Antibody Sales Value Comparison by Region: 2020 VS 2024 VS 2031 (US$ Million) |
Table 32 | :Global HER2 Antibody Sales Value by Region (2020-2025) & (US$ Million) |
Table 33 | :Global HER2 Antibody Sales Value Share by Region (2020-2025) |
Table 34 | :Global HER2 Antibody Sales Value by Region (2026-2031) & (US$ Million) |
Table 35 | :Global HER2 Antibody Sales Value Share by Region (2026-2031) |
Table 36 | :Global HER2 Antibody Sales Value by Country: 2020 VS 2024 VS 2031 (US$ Million) |
Table 37 | :Global HER2 Antibody Sales Value by Country (2020-2025) & (US$ Million) |
Table 38 | :Global HER2 Antibody Sales Value Market Share by Country (2020-2025) |
Table 39 | :Global HER2 Antibody Sales Value by Country (2026-2031) & (US$ Million) |
Table 40 | :Global HER2 Antibody Sales Value Market Share by Country (2026-2031) |
Table 41 | :Novartis AG Company Information |
Table 42 | :Novartis AG Business Overview |
Table 43 | :Novartis AG HER2 Antibody Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 44 | :Novartis AG HER2 Antibody Product Portfolio |
Table 45 | :Novartis AG Recent Development |
Table 46 | :Pfizer Company Information |
Table 47 | :Pfizer Business Overview |
Table 48 | :Pfizer HER2 Antibody Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 49 | :Pfizer HER2 Antibody Product Portfolio |
Table 50 | :Pfizer Recent Development |
Table 51 | :InvivoGen Company Information |
Table 52 | :InvivoGen Business Overview |
Table 53 | :InvivoGen HER2 Antibody Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 54 | :InvivoGen HER2 Antibody Product Portfolio |
Table 55 | :InvivoGen Recent Development |
Table 56 | :Genentech Inc Company Information |
Table 57 | :Genentech Inc Business Overview |
Table 58 | :Genentech Inc HER2 Antibody Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 59 | :Genentech Inc HER2 Antibody Product Portfolio |
Table 60 | :Genentech Inc Recent Development |
Table 61 | :Celltrion Company Information |
Table 62 | :Celltrion Business Overview |
Table 63 | :Celltrion HER2 Antibody Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 64 | :Celltrion HER2 Antibody Product Portfolio |
Table 65 | :Celltrion Recent Development |
Table 66 | :Bio-Techne Company Information |
Table 67 | :Bio-Techne Business Overview |
Table 68 | :Bio-Techne HER2 Antibody Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 69 | :Bio-Techne HER2 Antibody Product Portfolio |
Table 70 | :Bio-Techne Recent Development |
Table 71 | :Biocon Limited Company Information |
Table 72 | :Biocon Limited Business Overview |
Table 73 | :Biocon Limited HER2 Antibody Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 74 | :Biocon Limited HER2 Antibody Product Portfolio |
Table 75 | :Biocon Limited Recent Development |
Table 76 | :Abnova Corporation Company Information |
Table 77 | :Abnova Corporation Business Overview |
Table 78 | :Abnova Corporation HER2 Antibody Revenue (US$ Million) and Gross Margin (2020-2025) |
Table 79 | :Abnova Corporation HER2 Antibody Product Portfolio |
Table 80 | :Abnova Corporation Recent Development |
Table 81 | :Research Programs/Design for This Report |
Table 82 | :Authors List of This Report |
Table 83 | :Secondary Sources |
Table 84 | :Primary Sources |
List of Figures
Figure 1 | :HER2 Antibody Product Image |
Figure 2 | :Global HER2 Antibody Market Size (US$ Million), 2020 VS 2024 VS 2031 |
Figure 3 | :Global HER2 Antibody Market Size (2020-2031) & (US$ Million) |
Figure 4 | :Global HER2 Antibody Company Revenue Ranking in 2024 (US$ Million) |
Figure 5 | :Global Top 5 and 10 Company Market Share by Revenue in 2024 (US$ Million) |
Figure 6 | :Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024 |
Figure 7 | :Ado-trastuzumab Emtansine Image |
Figure 8 | :Lapatinib Image |
Figure 9 | :Pertuzumab Image |
Figure 10 | :Trastuzumab Image |
Figure 11 | :Everolimus Image |
Figure 12 | :Global HER2 Antibody Sales Value by Type (2020 VS 2024 VS 2031) & (US$ Million) |
Figure 13 | :Global HER2 Antibody Sales Value Share 2020 VS 2024 VS 2031 |
Figure 14 | :Global HER2 Antibody Sales Value Share by Type (2020-2031) |
Figure 15 | :Hospital Image |
Figure 16 | :Medical Center Image |
Figure 17 | :Global HER2 Antibody Sales Value by Application (2020 VS 2024 VS 2031) & (US$ Million) |
Figure 18 | :Global HER2 Antibody Sales Value Share 2020 VS 2024 VS 2031 |
Figure 19 | :Global HER2 Antibody Sales Value Share by Application (2020-2031) |
Figure 20 | :Global HER2 Antibody Sales Value Comparison by Region: 2020 VS 2024 VS 2031 (US$ Million) |
Figure 21 | :Global HER2 Antibody Sales Value Share by Region: 2020 VS 2024 VS 2031 |
Figure 22 | :North America HER2 Antibody Sales Value (2020-2031) & (US$ Million) |
Figure 23 | :North America HER2 Antibody Sales Value Share by Country (%), 2024 VS 2031 |
Figure 24 | :Europe HER2 Antibody Sales Value (2020-2031) & (US$ Million) |
Figure 25 | :Europe HER2 Antibody Sales Value Share by Country (%), 2024 VS 2031 |
Figure 26 | :Asia-Pacific HER2 Antibody Sales Value (2020-2031) & (US$ Million) |
Figure 27 | :Asia-Pacific HER2 Antibody Sales Value Share by Country (%), 2024 VS 2031 |
Figure 28 | :South America HER2 Antibody Sales Value (2020-2031) & (US$ Million) |
Figure 29 | :South America HER2 Antibody Sales Value Share by Country (%), 2024 VS 2031 |
Figure 30 | :Middle East & Africa HER2 Antibody Sales Value (2020-2031) & (US$ Million) |
Figure 31 | :Middle East & Africa HER2 Antibody Sales Value Share by Country (%), 2024 VS 2031 |
Figure 32 | :USA HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 33 | :USA HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 34 | :USA HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 35 | :Canada HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 36 | :Canada HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 37 | :Canada HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 38 | :Mexico HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 39 | :Mexico HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 40 | :Mexico HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 41 | :Germany HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 42 | :Germany HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 43 | :Germany HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 44 | :France HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 45 | :France HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 46 | :France HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 47 | :U.K. HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 48 | :U.K. HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 49 | :U.K. HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 50 | :Italy HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 51 | :Italy HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 52 | :Italy HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 53 | :Spain HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 54 | :Spain HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 55 | :Spain HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 56 | :Russia HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 57 | :Russia HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 58 | :Russia HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 59 | :Netherlands HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 60 | :Netherlands HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 61 | :Netherlands HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 62 | :Nordic Countries HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 63 | :Nordic Countries HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 64 | :Nordic Countries HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 65 | :China HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 66 | :China HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 67 | :China HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 68 | :Japan HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 69 | :Japan HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 70 | :Japan HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 71 | :South Korea HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 72 | :South Korea HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 73 | :South Korea HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 74 | :India HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 75 | :India HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 76 | :India HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 77 | :Australia HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 78 | :Australia HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 79 | :Australia HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 80 | :Southeast Asia HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 81 | :Southeast Asia HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 82 | :Southeast Asia HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 83 | :Brazil HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 84 | :Brazil HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 85 | :Brazil HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 86 | :Argentina HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 87 | :Argentina HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 88 | :Argentina HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 89 | :Chile HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 90 | :Chile HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 91 | :Chile HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 92 | :Colombia HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 93 | :Colombia HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 94 | :Colombia HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 95 | :Peru HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 96 | :Peru HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 97 | :Peru HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 98 | :Saudi Arabia HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 99 | :Saudi Arabia HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 100 | :Saudi Arabia HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 101 | :Israel HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 102 | :Israel HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 103 | :Israel HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 104 | :UAE HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 105 | :UAE HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 106 | :UAE HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 107 | :Turkey HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 108 | :Turkey HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 109 | :Turkey HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 110 | :Iran HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 111 | :Iran HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 112 | :Iran HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 113 | :Egypt HER2 Antibody Sales Value Growth Rate (2020-2031) & (US$ Million) |
Figure 114 | :Egypt HER2 Antibody Sales Value Share by Type, 2024 VS 2031 & (%) |
Figure 115 | :Egypt HER2 Antibody Sales Value Share by Application, 2024 VS 2031 & (%) |
Figure 116 | :Years Considered |
Figure 117 | :Research Process |
Figure 118 | :Key Executives Interviewed |
Request a Sample
Sample excerpt is intended to facilitate an informed purchase decision. Its purpose is not to offer free information or act as a substitute for the comprehensive product. In order to tailor the sample to your specific requirements, we will reach out to you to gather more details about your criteria.

Pharma & Healthcare
Global HER2 Antibody Market Outlook and Growth Opportunities 2025
Pages: 191
Complete Your Request
Customer reviews
- 0 out of 5
- 0 Reviews
5
4
3
2
1
No Rating Review Exist.
Write Review
Suggested Report
View MoreNo data found.